Abstract 196P
Background
We sought to explore whether the circulating proliferative T lymphocyte subtypes in patients with advanced gastric cancer (AGC) can be used as an indicator of prognosis.
Methods
Blood samples were collected from patients with AGC before treatment and analyzed by fluorescence-activated cell sorting analysis. Patients were divided into two groups based on the ratio of CD8+ T cells to CD4+ T cells and the ratio of CD8+ T cells to CD4+ T cells within Ki-67+ T cells. Survival between the groups was compared using the Kaplan-Meier method and the log-rank test. Multivariate analyses were also performed.
Results
A total of 92 patients enrolled in the study. The median age was 64.2 years, and the male-to-female ratio was 2.3:1. The median survival duration was 12.5 months. No significant differences in progression-free survival (PFS) and overall survival (OS) were observed between the groups with high and low CD8/CD4 ratios. However, the group with a high ratio of CD8/CD4 within proliferating T cells (n = 46) had a significantly longer OS (16.8 months vs. 11.3 months; p = 0.011) compared to the group with a low ratio of CD8/CD4 within proliferating T cells (n = 46). PFS did not vary between these proliferating CD8/CD4 ratio groups. A multivariate analysis indicated that the ratio of proliferating CD8 to CD4 was an independent prognostic factor for OS.
Conclusions
A high CD8/CD4 ratio among proliferating T cells in circulation could be associated with a better prognosis in patients with AGC receiving first-line chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract